Overview

Efficacy and Safety of Pimavanserin as Adjunctive Treatment for the Negative Symptoms of Schizophrenia

Status:
Recruiting

Trial end date:
2023-03-01

Target enrollment:

Participant gender:

Summary

To evaluate the efficacy and safety of adjunctive pimavanserin compared with adjunctive placebo in the treatment of negative symptoms of schizophrenia

Phase:

Phase 3

Details

Lead Sponsor:

ACADIA Pharmaceuticals Inc.

Treatments:

Pimavanserin